Patent application number | Description | Published |
20090137451 | Methods for Assessing Suitability of Cancer Patients for Treatment with Histone Deacetylase Inhibitors - This invention is in the field of cancer therapy and provides the use of E2F1 activity for assessing suitability of a cancer patient for treatment with histone deacetylase inhibitors (HDACIs). | 05-28-2009 |
20090318329 | METHODS FOR ASSESSING SUITABILITY OF CANCER PATIENTS FOR TREATMENT WITH HISTONE DEACETYLASE INHIBITORS - This invention is in the field of cancer therapy and provides the use of E2F1 activity for assessing suitability of a cancer patient for treatment with histone deacetylase inhibitors (HDACIs). | 12-24-2009 |
20100075915 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION - The present invention relates to a method of inducing apoptosis in a tumour cell as well as modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of general formula (I). In general formula A is C or N. R | 03-25-2010 |
20110053882 | METHODS AND COMPOUNDS FOR PREVENTING AND TREATING A TUMOUR - The invention relates to a method of preventing, inhibiting, arresting or reversing tumourigenesis in a cell as well as a method of inducing apoptosis in a tumour cell. The method includes increasing the amount and/or the activity of a DACT protein, or a functional fragment thereof, in the cell. Also provided is a pharmaceutical composition that comprises a compound of general formula (I), wherein A is CH or N, R | 03-03-2011 |
20110293746 | Modulation of Gsk-3Beta and Method of Treating Proliferative Disorders - There is provided methods and uses for promoting cell death, when combined with chemotherapeutic agents, in an abnormally proliferating cell, and for treating a proliferative disorder in a subject, which methods and uses involve contacting a cell with, or administering to a subject, an agent that modulates glycogen synthase kinase-3β activity to a cell that is being treated with a chemotherapeutic agent. | 12-01-2011 |
20120077841 | METHODS FOR CANCER THERAPY AND STEM CELL MODULATION - The present invention relates to a method of modulating pluripotency and/or self-renewing characteristics of a stem/progenitor cell. The method comprises administering to the respective cell a compound of the general formula (I) | 03-29-2012 |
20130123328 | METHODS AND COMPOSITIONS FOR TREATING CANCER - We describe a method of determining whether a cancer cell is likely to be resistant to treatment by an mTOR inhibitor. The method may comprise detecting PPP2R2B (GenBank Accession Number: NM_18167) in or of the cell. It may, alter-natively, or in addition, comprise detecting PDK1 (GenBank Accession Number: NM_002613), in or of the cell. The method may comprise detecting methylation of the PPP2R2B promoter in or of the cell. It may comprise detecting the expression and/or activity of PPP2R2B in or of the cell. It may comprise detecting PDK1 mediated Myc phosphorylation activity. Methods of choosing a treatment for an individual suffering from or suspected to be suffering from a cancer, determining whether an individual suffering from or suspected to be suffering from a cancer will respond to treatment by an mTOR inhibitor, increasing the sensitivity of a cancer cell to treatment by an mTOR inhibitor, for treating or preventing cancer in an individual suffering or suspected to be suffering from cancer are also provided. We further provide for a combination of an inhibitor of PDK1 expression and/or activity and an mTOR inhibitor for use in a method of treatment or prevention of cancer. | 05-16-2013 |
20130210024 | COMBINATION TREATMENT OF CANCER - The present technology relates to a method of treating cancer by sensitizing human tumours to DNA damaging therapies through activating FBXO32 expression. Transactivation of FBXO32 through the inhibition of EZH2, a histone methyltransferase, decreases p21 protein induction which results in the sensitization of human tumours to chemotherapy. The method further provides a prognostic method to determine if a combination treatment would be effective. | 08-15-2013 |
20140335106 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER - A method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof. | 11-13-2014 |